Quest Diagnostics (DGX) has been in a flurry of activities that significantly impacts its market standing and future projections. The company expanded its range once again, foraying into international markets with a nearly $1 billion deal to acquire
LifeLabs thus expanding into Canada. DGX also raised its full-year 2024 guidance following its Q2 earnings beating estimates, posting
Q2 earnings results of $2.40 B revenue which surpassed expectations. Furthermore, DGX exhibited its innovative streak through partnerships with companies like
Becton Dickinson (BDX) to develop companion diagnostics for conditions such as cancer, and
Broad Clinical Labs to evaluate whole-genome sequencing as a genetic test for developmental delay. These collabs highlight a clear focus on disease diagnosis and treatment improvements. Additionally, the acquisition of key laboratory assets from companies like
PathAI Diagnostics and
OhioHealth indicates a significant expansion of their diagnostic service offerings. Conversely, certain executives at DGX have recently sold company stock, indicating potential concerns regarding the company's performance.
Quest Diagnostics DGX News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 28 Jul 2024 15:49:36 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 2
